Company Profile
Sangamo Therapeutics
Company Overview
CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.
Our innovative pipeline focuses on the development of a diverse array of next-generation therapies including Probody cancer immunotherapies, Probody drug conjugates (PDCs), T-cell engaging Probody bispecifics and Probody-enabled chimeric antigen receptor natural killer (ProCAR-NK) cell therapies.